Elite Pharmaceuticals Reports Positive Topline Results from SequestOx™ Pilot Study

Elite Pharmaceuticals (OTCBB:ELTP) today reported positive topline results from a pilot study conducted for SequestOx™, Elite’s immediate release Oxycodone Hydrochloride product that incorporates its proprietary abuse-deterrent technology.
As quoted in the press release:

IMS reports approximately $400 million annually in revenue for the immediate release oxycodone generic market. There is currently one other approved, but not yet commercialized, abuse-deterrent product and many non-abuse deterrent generic products in this market. Immediate release oxycodone is one of the most highly abused opioids in the U.S.

Click here to read the full press release.